Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
143. WHO. Prioritizing second-line antiretroviral drugs for adults and adolescents: a public<br />
health approach – Re<strong>por</strong>t of a WHO working group meeting. Geneva: WHO; 2007.<br />
144. DHHS PoAGfAaADoHaHS. Gui<strong>de</strong>lines for the use of antiretroviral agents in HIV-1-infected<br />
adults and adolescents. 2009: Avai<strong>la</strong>ble from: http://www.aidsinfo.nih.gov/ContentFiles/<br />
AdultandAdolescentGL.pdf.<br />
145. Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly<br />
active antiretroviral therapy era: a re<strong>por</strong>t of 3 re<strong>la</strong>pses with acquired rifampin resistance<br />
following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis<br />
2009;48(10):1471-4.<br />
146. Ebraert H, Salu P. Toxic uveitis caused by pharmacodynamic <strong>int</strong>eractions of Rifabutin and<br />
protease inhibitors: a case re<strong>por</strong>t. Bull Soc B<strong>el</strong>ge Ophtalmol 2007;(303):57-60.<br />
147. WHO. Operational gui<strong>de</strong> for national tuberculosis control programmes on the <strong>int</strong>roduction<br />
and use of fixed-dose combination drugs. 2002: Avai<strong>la</strong>ble from: http://whq<strong>libdoc</strong>.<strong>who</strong>.<strong>int</strong>/<br />
hq/2002/WHO_CDS_TB_2002.308.pdf.<br />
148. Coutinho A MJ, Ekwaru J, Were W, R Bunn<strong>el</strong>l, Kaharuza F et al. , editor. Utility of routine<br />
viral load, CD4 c<strong>el</strong>l count, and clinical monitoring among HIV-infected adults in Uganda: A<br />
randomized trial. 15th Conference on Retroviruses and Op<strong>por</strong>tunistic Infections; 2008;<br />
Boston.<br />
149. Mugyenyi P WSHJ, Mun<strong>de</strong>ri P, Gibb D, Kityo C, et al., eds. Impact of routine <strong>la</strong>boratory<br />
monitoring over 5 years after antiretroviral therapy (ART) initiation on clinical disease<br />
progression of HIV-infected African adults: the DART trial final results 2009. 5th IAS<br />
Conference on HIV Pathogenesis, Treatment and Prevention; 2009; Cape Town.<br />
150. Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N, et al. HIV-1 viral load<br />
monitoring: an op<strong>por</strong>tunity to reinforce treatment adherence in a resource-limited setting<br />
in Thai<strong>la</strong>nd. Trans R Soc Trop Med Hyg 2009;103(6):601-6.<br />
151. Keiser O, Tweya H, Braitstein P, Dabis F, Macphail P, Boulle A, et al. Mortality after failure<br />
of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2009; 15:2, 251-258<br />
152. Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F, et al. Accuracy of WHO<br />
CD4 c<strong>el</strong>l count criteria for virological failure of antiretroviral therapy. Trop Med Int Health<br />
2009;14(10):1220-5.<br />
153. Phillips AN, Pil<strong>la</strong>y D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from<br />
monitoring of patients on antiretroviral therapy in resource-limited settings with viral load,<br />
CD4 c<strong>el</strong>l count, or clinical observation alone: a computer simu<strong>la</strong>tion mo<strong>de</strong>l. Lancet<br />
2008;371(9622):1443-51.<br />
154. Murri R, Lepri AC, Cicconi P, Poggio A, Arlotti M, Tositti G, et al. Is mo<strong>de</strong>rate HIV viremia<br />
associated with a higher risk of clinical progression in HIV-infected people treated with<br />
highly active antiretroviral therapy: evi<strong>de</strong>nce from the Italian cohort of antiretroviral-naive<br />
patients study. J Acquir Immune Defic Syndr 2006;41(1):23-30.<br />
143
Change language